Cellectar Biosciences announces 1-for-30 reverse stock split
Cellectar Biosciences (CLRB) announced a one-for-thirty reverse stock split of the company's common stock, par value $0.00001, which will become effective on Tuesday, June 24. The company's common stock will continue to trade under its current trading symbol, CLRB, on Nasdaq on a split-adjusted basis when the market opens on Tuesday, June 24, with the new CUSIP number 15117F880. As a result of the Reverse Stock Split, every 30 shares of the company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the company's common stock. The Reverse Stock Split will reduce the number of shares of common stock issued and outstanding from 54,361,197 shares to approximately 1,812,040. There will be no change to the number of authorized shares or the par value per share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest. As a result of the Reverse Stock Split, the number of shares of common stock available for issuance under the company's equity incentive plans will be proportionately affected.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
Maintained Quarterly Operational Profitability Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY Maintained Quarterly Positive Operating Cash Flow SHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year. Total operating expenses were RMB195.0 million (US$26.9 million), an improvement of 4.8% compared to RMB204.8 million in the same quarter of last year. As a percentage of net revenues, total operating expenses decreased by 30 basis points to 5.5% from 5.8% in the same quarter of last year, demonstrating continuous improvement in the Company's operational efficiency. Income from operations was RMB0.1 million (US$0.02 million), compared to RMB3.7 million in the same quarter of last year. As a percentage of net revenues, income from operations accounted for 0.004% this quarter as compared to 0.1% in the same quarter of last year. Non-GAAP income from operations (1) was RMB4.3 million (US$0.6 million), compared to RMB8.9 million in the same quarter of last year. As a percentage of net revenues, Non-GAAP income from operations accounted for 0.1% this quarter as compared to 0.3% in the same quarter of last year. Net cash from operating activities was RMB112.6 million (US$15.5 million), achieved another quarter of positive operating cash flow. (1) Non-GAAP income from operations represents income from operations excluding share-based compensation expenses. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, commented, "In the first quarter of 2025, we successfully navigated a persistently challenging macroeconomic environment to deliver another quarter of operational profitability and positive operating cash flow. Our net revenues remained stable at RMB 3.5 billion, demonstrating the resilience of our business model amidst market headwinds. Our ability to sustain profitability is a direct result of the operational discipline and strategic focus we have cultivated across the organization." "Our relentless focus on efficiency continues to bear fruit. We achieved a notable 4.8% year-over-year reduction in total operating expenses. More importantly, as a percentage of net revenues, our operating expenses improved to 5.5%, a decrease of 30 basis points from the same period last year, highlighting our capacity for continued operational improvement. This was driven by significant double-digit reductions in both our selling and marketing expenses and technology expenses, reflecting our commitment to prudent cost management." "Looking ahead, our strategy remains centered on leveraging technology to empower the healthcare value chain. We will continue to invest strategically in AI and digital solutions to enhance our supply chain, deepen customer engagement, and pioneer a seamless, one-stop shopping experience for our partners. With our fortified financial base and a clear focus on execution, we are well-positioned to capture the immense long-term opportunities in this exciting market and build a truly defensible, next-generation platform." First Quarter 2025 Financial Results Net revenues were RMB3,529 million (US$486.3 million), representing an increase of 0.02% from RMB3,528 million in the same quarter of last year. Gross segment profit (2) was RMB195.1 million (US$26.9 million). Due to an unfavorable macroeconomic environment, gross segment profit had a 6.4% decrease year-over-year. (In thousands RMB) For the three months ended March 31,20242025YoY B2B Net RevenueProduct 3,431,1723,457,2670.8 % Service 20,83716,971-18.6 % Sub-Total 3,452,0093,474,2380.6 % Cost of Products Sold(3) 3,261,1033,288,7470.8 % Segment Profit 190,906185,491-2.8 % Segment Profit % 5.5 %5.3 % (In thousands RMB) For the three months ended March 31,20242025YoY B2C Net RevenueProduct 72,20652,312-27.6 % Service 4,2142,729-35.2 % Sub-Total 76,42055,041-28.0 % Cost of Products Sold 58,79345,437-22.7 % Segment Profit 17,6279,604-45.5 % Segment Profit % 23.1 %17.4 % (2) Gross segment profit represents net revenues less cost of goods sold. (3) For segment reporting purposes, purchase rebates are allocated to the B2B segment and B2C segments primarily based on the amount of cost of products sold for each segment. Cost of products sold does not include other direct costs related to cost of product sales such as shipping and handling expense, payroll and benefits of logistic staff, logistic centers rental expenses and depreciation expenses, which are recorded in the fulfillment expenses. Cost of service revenue is recorded in the operating expense. Operating costs and expenses were RMB3.53 billion (US$486.3 million), representing an increase of 0.1% from RMB3.52 billion in the same quarter of last year. Cost of products sold was RMB3.33 billion (US$459.5 million), representing an increase of 0.4% from RMB3.32 billion in the same quarter of last year. Fulfillment expenses were RMB93.6 million (US$12.9 million), representing an increase of 5.7% from RMB88.5 million in the same quarter of last year. Fulfillment expenses accounted for 2.7% of net revenues this quarter as compared to 2.5% in the same quarter of last year. Selling and marketing expenses were RMB67.9 million (US$9.4 million), representing a decrease of 15.5% from RMB80.4 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB1.6 million for the quarter and RMB1.9 million for the same quarter last year, respectively, selling and marketing expenses as a percentage of net revenues accounted for 1.9% in the quarter as compared to 2.2% in the same quarter of last year. General and administrative expenses were RMB18.3 million (US$2.5 million), representing a decrease of 3.8% from RMB19.1 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB1.9 million for the quarter and RMB2.1 million for the same quarter last year, respectively, general and administrative expenses as a percentage of net revenues accounted for 0.5% this quarter, maintaining the same as last year. Technology expenses were RMB15.5 million (US$2.1 million), representing a decrease of 15.6% from RMB18.3 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB0.6 million for the quarter and RMB1.2 million for the same quarter last year, respectively, technology expenses as a percentage of net revenues accounted for 0.4% in the quarter as compared to 0.5% in the same quarter of last year. Income from operations was RMB0.1 million (US$0.02 million), compared to RMB3.7 million in the same quarter of last year. As a percentage of net revenues, income from operations accounted for 0.004% this quarter as compared to 0.1% in the same quarter of last year. Non-GAAP income from operations was RMB4.3 million (US$0.6 million), compared to RMB8.9 million in the same quarter of last year. As a percentage of net revenues, Non-GAAP income from operations accounted for 0.1% this quarter as compared to 0.3% in the same quarter of last year. Net loss was RMB7.3 million (US$1.0 million), compared to RMB2.7 million in the same quarter of last year. As a percentage of net revenues, net loss accounted for 0.2% this quarter as compared to 0.1% in the same quarter of last year. Non-GAAP net loss (4) was RMB3.2 million (US$0.4 million), compared to Non-GAAP net income of RMB2.5 million in the same quarter of last year. Net loss attributable to ordinary shareholders was RMB17.6 million (US$2.4 million), compared to RMB13.8 million in the same quarter of last year. As a percentage of net revenues, net loss attributable to ordinary shareholders accounted for 0.5% this quarter as compared to 0.4% in the same quarter of last year. Non-GAAP net loss attributable to ordinary shareholders (5) was RMB13.5 million (US$1.9 million), compared to RMB8.6 million in the same quarter of last year. As a percentage of net revenues, non-GAAP net loss attributable to ordinary shareholders accounted for 0.4% this quarter as compared to 0.2% in the same quarter of last year. (4) Non-GAAP net loss represents net loss excluding share-based compensation expenses, net of tax. Considering the impact of accretion of redeemable non-controlling interest for the first quarter 2025, non-GAAP net loss is used as a meaningful measurement of the operation performance of the Company.(5) Non-GAAP net loss attributable to ordinary shareholders represents net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax. As of March 31, 2025, the Company held cash and cash equivalents, restricted cash and short-term investments totaling RMB556.8 million (US$76.7 million), compared to RMB518.3 million as of December 31, 2024. To date, amount of RMB1.09 billion has been included in the balances of redeemable non-controlling interests and accrued expenses and other current liabilities. This amount is owed to a group of investors of 1 Pharmacy Technology pursuant to equity investments made in 2020, as previously disclosed. 111 has received redemption requests from certain of such investors in accordance with the terms of their initial investments in 1 Pharmacy Technology. Following communication and negotiation to date, the Company has reached agreements with or received commitment letters from investors representing approximately 96.79% of the total amount to reschedule the repayments, allowing for phased repayments at extended periods, if the holders exercise their redemption rights. A portion of the redemption has already been paid upon signing of these agreements. For further details on the terms of 111's arrangements with these investors, please see "Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources" in the Company's annual report for the fiscal year ended December 31, 2024. Use of Non-GAAP Financial Measures In evaluating the business, the Company considers and uses non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS, as supplemental measures to review and assess its operating performance. The Company defines non-GAAP income from operations as income from operations excluding share-based compensation expenses. The Company defines non-GAAP net income (loss) as net loss excluding share-based compensation expenses, net of tax. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax. The Company defines non-GAAP loss per ADS as net loss attributable to ordinary shareholders per ADS excluding share-based compensation expenses, net of tax per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. The Company believes that non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in income from operations and net loss. Share-based compensation expenses is a non-cash expense that varies from period to period. As a result, management excludes the items from its internal operating forecasts and models. Management believes that the adjustments for share-based compensation expenses provide investors with a reasonable basis to measure the company's core operating performance, in a more meaningful comparison with the performance of other companies. The Company believes that non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP income from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company's operations. Further, the non-GAAP financial measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. The Company compensates for these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP measures, all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure. Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release. Exchange Rate Information Statement This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.2567 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of March 31, 2025. Forward-Looking Statements This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. About 111, Inc. 111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring. For more information on 111, please visit: 111, Inc. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share data) As of As ofDecember 31, 2024 March 31, 2025RMB RMBUS$ ASSETS Current assets: Cash and cash equivalents 462,289 485,73666,936 Restricted cash 56,043 71,0969,797 Short-term investments - -- Accounts receivable, net 413,101 266,58236,736 Notes receivable 78,827 94,76513,059 Inventories 1,387,403 1,342,798185,043 Prepayments and other current assets 251,994 224,21830,898 Total current assets 2,649,657 2,485,195342,469 Property and equipment, net 32,903 30,8824,256 Intangible assets, net 1,437 1,259173 Long-term investments - -- Other non-current assets 14,682 14,1431,949 Operating lease right-of-use asset 89,071 76,41010,530 Total assets 2,787,750 2,607,889359,377LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICITCurrent liabilities: Short-term borrowings 160,981 148,50020,464 Accounts payable 1,721,425 1,680,164231,531 Accrued expense and other current liabilities 460,173 346,01847,684 Total current liabilities 2,342,579 2,174,682299,679 Long-term operating lease liabilities 55,448 46,7026,436 Other non-current liabilities 8,961 8,6321,190 Total liabilities 2,406,988 2,230,016307,305MEZZANINE EQUITY Redeemable non-controlling interests 1,038,914 1,051,913144,957SHAREHOLDERS' DEFICIT Ordinary shares Class A 33 335 Ordinary shares Class B 25 253 Treasury shares (5,887) (5,887)(811) Additional paid-in capital 3,172,820 3,176,937437,794 Accumulated deficit (3,883,992) (3,901,641)(537,661) Accumulated other comprehensive income 74,357 74,27710,236 Total shareholders' deficit (642,644) (656,256)(90,434) Non-controlling interest (15,508) (17,784)(2,451) Total deficit (658,152) (674,040)(92,885) Total liabilities, mezzanine equity and deficit 2,787,750 2,607,889359,377 111, Inc. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except for share and per share data) For the three months ended March 31,20242025RMBRMBUS$ Net revenues 3,528,4293,529,279486,348 Operating costs and expenses: Cost of products sold (3,319,896)(3,334,184)(459,463) Fulfillment expenses (88,523)(93,566)(12,894) Selling and marketing expenses (80,360)(67,908)(9,358) General and administrative expenses (19,074)(18,341)(2,527) Technology expenses (18,309)(15,459)(2,130) Other operating income, net 1,45732445 Total operating costs and expenses (3,524,705)(3,529,134)(486,327) Income from operations 3,72414521 Interest income 1,9661,254173 Interest expense (7,982)(8,732)(1,203) Foreign exchange (loss) gain (219)426 Other loss, net (123)-- Loss before income taxes (2,634)(7,291)(1,003) Income tax expense (51)(16)(2) Net loss (2,685)(7,307)(1,005) Net loss attributable to non-controlling interest (173)1,745240 Net loss attributable to redeemable non-controlling interest 28944561 Adjustment attributable to redeemable non-controlling interest (11,206)(12,532)(1,727) Net loss attributable to ordinary shareholders (13,775)(17,649)(2,431) Other comprehensive loss Unrealized gains of available-for-sale securities, (34)-- Realized gains of available-for-sale debt securities 177-- Foreign currency translation adjustments 620(80)(11) Comprehensive loss (13,012)(17,729)(2,442) Loss per ADS: Basic and diluted (1.60)(2.00)(0.20) Weighted average number of shares used in computation of loss per share Basic and diluted 171,220,973173,119,578173,119,578 111, Inc. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) For the three months ended March 31,20242025RMBRMBUS$ Net cash provided by operating activities 108,438112,59915,516 Net cash provided by (used in) investing activities 29,742(1,088)(150) Net cash used in financing activities (155,471)(72,981)(10,057) Effect of exchange rate changes on cash and cash equivalents, and restricted cash 1,072(30)(4) Net (decrease) increase in cash and cash equivalents, and restricted cash (16,219)38,5005,305 Cash and cash equivalents, and restricted cash at the beginning of the period 623,548518,33271,428 Cash and cash equivalents, and restricted cash at the end of the period 607,329556,83276,733 111, Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results (In thousands, except for share and per share data) For the three months ended March 31,20242025RMBRMBUS$ Income from operations 3,72414521 Add: Share-based compensation expenses 5,1714,115567 Non-GAAP income from operations 8,8954,260588 Net loss (2,685)(7,307)(1,005) Add: Share-based compensation expenses, net of tax 5,1714,115567 Non-GAAP net income (loss) 2,486(3,192)(438) Net loss attributable to ordinary shareholders (13,775)(17,649)(2,431) Add: Share-based compensation expenses, net of tax 5,1714,115567 Non-GAAP net loss attributable to ordinary shareholders (8,604)(13,534)(1,864) Loss per ADS(6): Basic and diluted (1.60)(2.00)(0.20) Add: Share-based compensation expenses per ADS(6), net of tax 0.600.400.00 Non-GAAP loss per ADS(6) (1.00)(1.60)(0.20) (6) Every one ADS represents twenty Class A ordinary shares. View original content: SOURCE 111, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2025 financial results and provided a corporate update. 'We have had a great start to 2025 both in terms of product development and achieving business milestones. Progress continues well and on track with our GABAB PAM drug candidate in chronic cough. Positive data from this program in multiple preclinical models was recently presented at the prestigious American cough conference. We have also regained rights to our Phase 2 mGlu2 PAM asset, ADX71149,' said Tim Dyer, CEO of Addex. 'Solidifying our position to use mGlu5 NAMs in brain injury, we entered an option agreement with Sinntaxis to gain access to additional intellectual property. Our plan is to explore further the clinical activity of dipraglurant in this indication. Finally, our partner, Indivior, indicated that they have advanced their GABAB PAM clinical candidate through IND enabling studies, providing additional validation of our allosteric modulation approach.' Operating Highlights: GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in multiple models of disease Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced their GABAB PAM program for substance use disorders successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering use of mGlu5 NAM in brain injury recovery Key Q1 2025 Financial Data CHF' thousands Q1 2025 Q1 2024 Change Income 71 235 (164) R&D expenses (156) (245) 89 G&A expenses (521) (778) 257 Total operating loss (606) (788) 182 Finance result, net (19) 53 (72) Share of net loss of associates (848) - (848) Net loss from continuing operations (1,473) (735) (738) Net loss from discontinued operations - (2,352) 2352 Net loss for the period (1,473) (3,087) 1,614 Basic and diluted net loss per share:From continuing operations (0.01) (0.01) - From discontinued operations - (0.02) (0.02) Total basic and diluted net loss per share (0.01) (0.03) (0.02) Net decrease in cash during the period (517) (2,237) 1,720 Cash and cash equivalents 2,825 1,628 1,197 Shareholders' equity 8,296 (1,373) 9,669 Financial Summary:Income decreased by CHF 0.2 million during the three-month period ended March 31, 2025 compared to the same period ended March 31, 2024, primarily due to the completion of the service agreement with Indivior on June 30, 2024. R&D expenses decreased by CHF 0.1 million during three-month period ended March 31, 2025 compared to the same period ended March 31, 2024 primarily due to lower GABAB PAM outsourced R&D expenses as we successfully completed the research phase of our agreement with Indivior on June 30, 2024. G&A expenses decreased by CHF 0.3 million during the three-month period ended March 31, 2025 compared to the same period ended March 31, 2024 primarily due to reduced legal fees. Net loss decreased by CHF 1.6 million during the three-month period ended March 31, 2025 compared to the same period ended March 31, 2024, primarily due to the discontinued loss of CHF 2.4 million incurred during the three-month period ended March 31, 2024, related to activities divested on April 2, 2024, partially offset by the share of the net loss of Neurosterix Group incurred for CHF 0.9 million during the three-month period ended March 31, 2025. Basic and diluted loss per share amounted to CHF 0.01 per share for the three-month period ended March 31, 2025 compared to a basic and diluted loss per share of CHF 0.03 for the same period ended March 31, 2024. Cash and cash equivalents increased to CHF 2.8 million at March 31, 2025, compared to CHF 1.6 million at March 31, 2024. The increase of CHF 1.2 million between March 31, 2025 and March 31, 2024 is primarily due to the gross proceeds of CHF 5.0 million from the Neurosterix Transaction received in April 2024, partially offset by the cash used in operating activities. Q1 2025 Consolidated Financial Statements:The Q1 2025 financial report can be found on the Company's website in the investor/download section here. Conference Call Details:A conference call will be held today, June 19, 2025, at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to review the financial results. Tim Dyer, Chief Executive Officer and Mikhail Kalinichev, Head of Translational Science will deliver a brief presentation followed by a Q&A session. Joining the Conference Call: Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN. In the 10 minutes prior to the call's start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number. Webcast registration URL: Conference call registration URL: About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@ Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Interactive Brokers Group, Inc. (IBKR) Dips More Than Broader Market: What You Should Know
In the latest trading session, Interactive Brokers Group, Inc. (IBKR) closed at $52.60, marking a -74.73% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.03%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.13%. Heading into today, shares of the company had lost 1.03% over the past month, outpacing the Finance sector's loss of 1.73% and lagging the S&P 500's gain of 0.6%. The upcoming earnings release of Interactive Brokers Group, Inc. will be of great interest to investors. The company is expected to report EPS of $1.73, down 1.7% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.32 billion, up 7.65% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $7.06 per share and revenue of $5.36 billion, indicating changes of +0.43% and +2.62%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for Interactive Brokers Group, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Interactive Brokers Group, Inc. is currently a Zacks Rank #4 (Sell). Valuation is also important, so investors should note that Interactive Brokers Group, Inc. has a Forward P/E ratio of 29.51 right now. For comparison, its industry has an average Forward P/E of 14.59, which means Interactive Brokers Group, Inc. is trading at a premium to the group. We can additionally observe that IBKR currently boasts a PEG ratio of 2.82. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. IBKR's industry had an average PEG ratio of 1.2 as of yesterday's close. The Financial - Investment Bank industry is part of the Finance sector. With its current Zacks Industry Rank of 148, this industry ranks in the bottom 40% of all industries, numbering over 250. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Interactive Brokers Group, Inc. (IBKR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
